Related Experiment Video

Updated: Apr 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K

Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial

Mohamed Farag1, Diana A Gorog

  • 1Department of Cardiology, East & North Hertfordshire NHS Trust, Hertfordshire, UK.

Future Cardiology
|March 12, 2015
PubMed

Insights

Rivaroxaban offers a safe and effective alternative to traditional warfarin for preventing blood clots in nonvalvular atrial fibrillation (NVAF) patients undergoing cardioversion. This study found rivaroxaban comparable to VKAs for safety while potentially speeding up cardioversion procedures.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Vitamin K antagonists (VKAs) are the standard for thromboprophylaxis in nonvalvular atrial fibrillation (NVAF) patients undergoing cardioversion.
  • Non-VKA oral anticoagulants (NOACs) offer potential alternatives, necessitating safety and efficacy evaluations.

Purpose of the Study:

  • To compare the safety and efficacy of rivaroxaban versus dose-adjusted VKAs for thromboprophylaxis in NVAF patients scheduled for cardioversion.
  • To assess the impact of rivaroxaban on the timing of cardioversion procedures.

Main Methods:

  • Prospective trial (X-VeRT) comparing rivaroxaban (20 mg daily or 15 mg if CrCl 30-49 ml/min) with dose-adjusted VKAs.
  • Patients with NVAF undergoing cardioversion were randomized.
  • Cardioversion timing was either early (1-5 days) or delayed (3-8 weeks).

Main Results:

  • Rivaroxaban demonstrated a similar incidence of adverse cardiovascular events and bleeding compared to VKA.
  • Rivaroxaban significantly reduced the time to cardioversion in patients undergoing delayed cardioversion.
  • No significant difference in the primary safety endpoint between rivaroxaban and VKA groups.

Conclusions:

  • Rivaroxaban is a safe and effective alternative to VKAs for thromboprophylaxis in NVAF patients undergoing elective cardioversion.
  • Rivaroxaban may facilitate earlier cardioversion in certain patient subgroups.
  • The findings support the use of rivaroxaban in this clinical setting.
Keywords:
atrial fibrillationcardioversionoral anticoagulantsrivaroxabanwarfarin

More Related Videos

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

730
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
473
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
482
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
445
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
637